SOD1 and Parkinson disease: The rotenone optimally produced pathological and clinical symptoms relatable to PD, as demonstrated by the significant drop in striatal DA and anti-oxidative stress biomarkers (GSH and SOD) and the neurodegenerative changes in the H&E-stained sections of the rotenone-treated group when compared to the normal rats.